VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Vericel Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$40.37+0.24 (+0.60%)

Close on Oct 19, 2026

Market cap: $2.11B
P/E (TTM): 96.1
Dividend yield: –

Vericel Corp income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2010 2010-06-30	FY 2009 2009-06-30
Revenue	276	237	198	164	156	124	118	91	64	54	51	29	0.02	0.02	0.09	0.18
Cost of Revenue	71	65	62	55	50	40	38	32	30	28	26	17	0.00	0.01	0.03	0.11
Gross Profit	206	172	136	110	106	84	80	59	34	26	25	12	0.02	0.02	0.06	0.07
Research & Development	28	25	21	20	16	13	30	14	13	15	19	21	15	26	13	11
Selling, General & Admin	167	143	121	107	98	69	61	49	36	27	22	14	5.88	7.75	5.20	4.95
Selling & Marketing	90	82	69	61	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	77	61	52	46	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	195	168	142	127	114	82	92	63	49	45	41	35	21	34	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	–	–	–	21	34	18	16
Operating Income	11	4.52	-6.46	-17	-7.85	2.37	-11	-3.91	-15	-19	-17	-24	-21	-34	-18	-16
Interest Expense	0.63	0.61	0.60	0.37	0.00	0.01	0.01	0.03	0.09	0.02	0.01	0.01	0.01	0.01	0.04	0.07
Interest & Investment Income	7.01	6.41	4.63	1.34	0.22	0.69	1.61	0.90	0.01	0.01	0.04	0.02	0.02	0.05	0.12	0.30
Other Non-Operating Income	6.33	5.99	4.10	1.07	0.27	0.67	1.59	-4.23	-2.30	-0.32	0.33	3.61	5.34	4.29	3.25	0.11
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	0.10	–	3.00	0.41	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	-0.03	0	-0.02	0.12	0	0.04	-0.14	0	–	–	–
Pretax Income	17	11	-2.37	-16	-7.58	3.04	-9.67	-8.14	-17	-20	-16	-20	-16	-29	-15	–
Income Tax Expense	0.86	0.15	0.81	0.72	-0.11	0.18	0	0	0	0	0	0	0	–	–	–
Net Income	17	10	-3.18	-17	-7.47	2.86	-9.67	-8.14	-17	-20	-16	-20	-16	-29	-15	–
Preferred Dividends	–	–	–	–	–	–	–	0	0	7.58	6.74	6.01	5.35	3.99	–	–
Net Income to Common	–	–	–	–	–	–	–	-8.14	-17	-27	-23	-26	-21	-33	-15	-16
EPS (Basic)(per share)	0.33	0.21	-0.07	-0.35	-0.16	0.06	-0.22	-0.20	-0.52	-1.18	-0.97	-2.23	-6.95	-16.25	-11.80	-18.00
EPS (Diluted)(per share)	0.32	0.20	-0.07	-0.35	-0.16	0.06	-0.22	-0.20	-0.52	-1.18	-0.97	-2.23	-6.95	-16.25	-11.80	-18.00
Shares Outstanding (Basic, Weighted)(shares)	50	49	48	47	46	45	44	40	33	23	24	12	3.02	2.06	1.24	0.89
Shares Outstanding (Diluted, Weighted)(shares)	52	52	48	47	46	47	44	40	33	23	24	12	3.02	2.06	1.24	0.89
EBITDA	23	10	-1.83	-13	-4.89	4.76	-9.55	-2.48	-13	-17	-15	-23	-20	-33	-17	-15

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 74.6%
Operating margin: 6.0%
Net margin: 7.9%
Return on equity, FY2025: 5.1%

Financial strength

Current ratio: 5.04
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 238.6%

Valuation

P/E ratio: 96.1
Price to sales: 6.89
Price to book: 5.71
Dividend yield: –